Trial Profile
Phase I/II dose-escalation study of the investigational trifunctional bispecific anti-CD20 x anti-CD3 antibody FBTA05 in relapsed or refractory chronic lymphocytic leukemia.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 29 Aug 2011
Price :
$35
*
At a glance
- Drugs FBTA 05 (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Neovii Biotech
- 29 Aug 2011 New trial record